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Abstract In the well-developed countries, breast can-
cer-related mortality rates show decreasing tendency. 
Relapse occurs only in about one-fourth of all patients. 
According to randomized studies, no survival benefit is 
provided in these cases by practising intensive follow-
up including instrumental studies to actively search for 
distant metastases. The most important role of patient 
surveillance is to detect early-stage, potentially cur-
able isolated local/regional relapses or second primary 
breast cancers. More and more attention is given to the 
early detection and treatment of the side-effects of the 
therapy on the other hand. Even a “minimalist” follow-
up practice maintains the relationship with the patient 
that is important for getting reassurance for compliance 
with adjuvant endocrine therapies, assistance in case 
of symptoms of metastasis, or if medical or social deci-
sions are to be made. Sometimes psychological prob-
lems occur, which necesitate special support. In routine 
practice, regular visits including patient history, physi-
cal examination, and breast imaging studies on a 6–12 
monthly basis for up to 5 years and yearly thereafter with 
the maintenance of a supportive relationship with the 
patient are recommended. Chest, abdominal or bone 
imaging studies, laboratory or tumor marker tests are 
justified only in suspicion of relapse.
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Introduction
The practice of follow-up of breast cancer patients is 
still inconsistent after the completion of hospital-based 
treatments (surgery, chemotherapy, and radiotherapy). 
Despite the fact that solid, evidence-based guidelines 
exist for the rational surveillance of breast cancer patients 
after the curative-intent adjuvant therapy [1–3], some 
physicians still favor performing intensive follow-up uti-
lizing instrumental studies with the aim of early detec-
tion of distant metastases. Nowadays, about half of the 
breast cancers are mammography screening-detected, 
which predicts an excellent outcome with cure in more 
than 90 % of the cases. Thanks to increasing breast can-
cer awareness, even non-screen detected cancers are 
diagnosed at a relatively earlier stage than before, and 
the efficiency of adjuvant treatments is ever improving. 
Thus, in the well-developed countries, relapse rates and 
breast cancer-related mortality are decreasing. On the 
other hand, the mechanism of development, detection, 
and therapy of the treatment side-effects in both the 
short-term (endocrine therapies) and long-term (radio-
therapy) are more and more well understood, prevented, 
or treated, just as the psychological burden related to the 
disease and treatments. While keeping in mind ethical 
issues, the best utilization of financial resources must be 
also an issue when the optimum follow-up practice is to 
be defined.
One of the most important roles of follow-up after 
the primary treatment of operable breast cancer is the 
early detection of potentially curable isolated local/
regional relapse or a second primary breast cancer, and 
the other is the detection of the side-effects of the therapy 
on the other hand. Even a “minimalist” follow-up prac-
tice maintains the relationship with the patient that is 
important for getting reassurance for compliance with 
adjuvant endocrine therapy, assistance in case of symp-
toms of metastasis, or if medical or social decisions are 
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to be made [4]. Sometimes psychological problems occur 
which necessitate special support (Table 1).
Intensive versus “rational” surveillance
Four randomized studies and a meta-analysis provide 
solid basis and consistent evidence in favor of practising 
a simple clinical follow-up confined to clinical visit and 
mammography, and against instrumental tests to detect 
distant metastases. In the first study, including a cohort 
of 1,243 patients, although, the patients on the intensive 
follow-up arm were diagnosed earlier with metastases, 
no survival benefit occurred between the arms [5], even if 
the survival analysis was extended to 10 years [6]. A simi-
lar trial enrolling 1,320 patients gave identical results after 
a follow-up time of 71 months [7]. Health-related quality 
of life did not differ either according to the method of fol-
low-up. A third randomized study including 296 patients, 
indicated that most tumor recurrences were interval 
events detected between the regular visits, independent 
of having been followed-up in an intensive or “minimal-
ist” way. No significant difference was detected in most 
of the quality of life dimensions among the groups [8]. 
Kokko et al. [9], studied both the type and timing of sur-
veillance on survival and costs. The conclusion was that 
neither the frequency of the visits nor its intensity had 
any effect on the survival of patients. Intensive follow-up 
increase the costs of follow-up 2.2 times [9]. The data of 
the first three studies were investigated in the Cochrane 
Database, the pooled data analysis confirmed that no 
survival advantage is provided by an intensive follow-up 
approach, and survival is similar among the subgroups 
according to age or risk indicators [10].
In an early study, Winchester et al. [11] analyzed the 
time of metastasis detection in 87 patients with dissemi-
nated disease. Most of the patients had symptoms that 
necessitated staging examinations, and only in three 
cases was the imaging study or laboratory finding the 
one that revealed the distant metastasis [11]. Further-
more, since diagnostic tests in asymptomatic patients 
often provide ambiguous or false-positive results, further 
sophisticated examinations might be needed that easily 
raise anxiety in the patient [12–14].
Obviously, a “minimalist” follow-up program is less 
expensive than its intensive counterpart [9], and prac-
tice non-compliant with guidelines needs 2.2–3.6 times 
greater resources [15]. According to the study of Gulliford 
et al. [16], average-risk patients prefer less frequent fol-
low-up, and equally cooperate with routine or intensive 
surveillance [4, 17].
Monitoring local/regional relapse and second 
primary breast cancer
The incidence of local or regional relapses depends on 
the patient population and the quality of the primary 
care, but, in general is well below 10 %. Local or regional 
relapses most often occur during the first 3–5 years after 
surgery. One out of four local relapses cause the death of 
the patient [18]. The risk of local or regional relapse after 
the primary management, varies according to the mode 
of detection, the mammographic appearance, the tumor 
size, the histological type (triple negative and HER2-
positive tumors!), the presence of extensive intraductal 
component and the distribution of the lesion (multifo-
cality, diffuse lesions!), the surgical margin status, the 
type of lymph node surgery and the nodal status, the age 
of the patient (young age especially in DCIS!), the use and 
quality of radiotherapy and systemic therapy [19–21]. The 
incidence of metachronous second breast cancer (in the 
opposite breast, or in the operated breast outside of the 
primary tumor’s location) is 0.5–1.0 % per subsequent 
year, the odds ratio of developing it after the first breast 
cancer is about 1.25. Both local relapses and second pri-
mary breast cancers may be well controlled if the tumor 
is detected at a small size. Therefore, careful, preferably 
risk-adapted monitoring is suggested. Breast imaging of 
the operated breast should be examined by ultrasound 
and mammography every 6–12 months for 2 years, and 
yearly thereafter, while the opposite breast yearly. In 
dubious cases, complex clinical breast examination is 
needed to clarify the diagnosis.
Monitoring side-effects of therapy
Local therapy
Surgery itself may cause numbness, pain, and/or swell-
ing of the breast or the arm. Radiotherapy is widely prac-
tised; however, radiogenic side-effects are relatively rare. 
Few months after the radiotherapy radiogenic pneumo-
nitis and later on localized pulmonary fibrosis of the lung 
may occur [19, 22]. Radiogenic hypothyreosis is rare, but 
should be diagnosed by the symptoms. The fibrosis of the 
soft tissues may cause breast pain and worsen cosmetic 
outcome, or may contribute to the lymphedema of the 
arm [19, 23]. In the long-term, the development of isch-
emic heart disease due to the damage of the left anterior 
Table 1 The goals of follow-up of patients after hospital-
based treatments
Monitoring cancer relapse 
or second primary
Monitor for local/regional relapse
Monitor for signs or symptoms of metastasis
Monitor for second primary breast cancer
Maintenance of 
compliance with therapy 
and management of 
side-effects
Monitor for side-effects of ongoing therapy 
and patient reassurance
Monitor, counsel and manage for side-effects 
of already completed therapies
Patient rehabilitation Psychosocial support
Breast cosmesis
Childbearing issues
Social decisions
Genetic counseling
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social and sexual functioning that adversely affect qual-
ity of life. The majority of patients report satisfying func-
tioning after the completion of chemotherapy and easily 
return to normal life. Occasionally, patients may need 
the help of the physician performing the follow-up, or 
the assistance of a psychologist or psychiatrist.
Genetic counseling
Some of the women request or need genetic counseling 
for learning their inherited risk for familial breast cancer 
syndromes. These patients should be referred to genetic 
tests if consented after discussing the risks and benefits. 
Clinical guidelines recommend referral in the following 
situations [1, 29]:
1. Ashkenazi Jewish heritage
2. History of ovarian cancer at any age in the patient or 
any first- or second-degree relatives
3. Any first-degree relative with a history of breast cancer 
diagnosed before the age of 50
4. Two or more first- or second-degree relatives diag-
nosed with breast cancer at any age
5. Patient or relative with diagnosis of bilateral breast 
cancer
6. History of breast cancer in a male relative.
Post scriptum
New developments in oncology may make a significant 
impact on the natural course of the disease. The discov-
ery of the platinum agents’ effects on testicular cancer 
was the first in line that caused a change never ever seen 
before in advanced solid tumors. Then, the application 
of anti-HER2 therapies in HER2-positive breast cancer, 
the success of neoadjuvant chemotherapy in certain 
breast cancers, or the modern view and management 
practice of metastatic cancers such as colorectal cancer, 
to either perform metastasectomy and/or temper the 
disease to a chronic status amenable to be kept under 
control.
The rapidly developing era utilizing sophisticated 
diagnostic methods and individualized molecular tar-
geted therapy might bring new possibilities in the man-
agement of metastatic breast cancer. If so, it may turn out, 
that in high-risk patients, the early detection of metasta-
ses would yield benefit in terms of possible cure or the 
prolongation of survival. At present, however, yet no 
such perspectives are apparent, thus follow-up should 
be restricted to evidence-based guidelines (Table  2). 
The surveillance of patients may be equally efficiently 
performed by specialists (surgeons, oncologists, and 
radiotherapists), general practitioners, or even trained 
nurses adherent to guidelines; follow-up practice should 
be organized according to resources, traditions, or other 
factors [1, 30].
descending coronary artery [19, 24, 25], or radiogenic 
second cancers may occur [26]. Alertness during follow-
up is essential since specific therapy or intervention may 
control the abnormality.
Systemic therapy
During the follow-up period, chronic or late side-effects 
of chemotherapy are relevant. Thus, symptoms due to 
premature menopause, fatigue, cognitive dysfunction 
(“chemo brain”), osteoporosis, rarely cardiac dysfunc-
tion (to which Herceptin therapy may contribute to) or 
secondary malignancies occur [4]. The adverse effects of 
endocrine therapies include genitourinary problems and 
sexual dysfunction, weight gain, osteoporosis, arthralgia, 
effects on the nervous system and cognitive dysfunction, 
thus deteriorating health-related quality of life [4, 27]. 
Some long-term, even definitive side-effects may be 
the consequence of both chemotherapy and endocrine 
therapy.
Patients after chemotherapy/Herceptin therapy may 
need cardiac surveillance if cardiac dysfunction has been 
detected during the treatment or if suspected by spe-
cific symptoms. Osteoporosis should be monitored and 
treated in patients with early premenopause or on aro-
matase inhibitor therapy. Tamoxifen therapy increases 
the risk of thromboembolic events, endometrial hyper-
plasia/cancer, stroke, and cataract formation. Those 
who complain about musculoskeletal problems should 
be admitted to physiotherapist. Various gynecological 
problems may be ameliorated with hormonal or non-
hormonal interventions. Fatigue may be controlled with 
special training or relaxation techniques.
Fertility issues
Some patients may wish to bear children after primary 
management of breast cancer [4, 28]. They intend to know 
the potential to get pregnant, and whether pregnancy 
may deteriorate their prognosis. Also, the possible tera-
togenic effect of the previous chemotherapy on the fetus 
is a concern. These issues should be carefully and openly 
discussed and managed with the patient and her gyne-
cologist. At present, there is no evidence for the adverse 
effect of pregnancy on the underlying disease, however, 
only restrospective analyses have been performed [4, 28]. 
Breast feeding may be possible even after breast-con-
serving surgery and postoperative radiotherapy in less 
than half of the patients; in the others, unilateral lacta-
tion may be sufficient [28].
Psychosocial support
The diagnosis of breast cancer and its treatment may 
induce anxiety, depression, and problems with physical, 
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Take-home message
Following the primary treatment of breast cancer, regu-
lar visits including physical examination, breast imag-
ing studies on a 6–12 monthly basis for up to 5 years, and 
yearly thereafter, with the maintenance of a supportive 
relationship with the patient are recommended. Chest, 
abdominal or bone imaging studies, laboratory or tumor 
marker tests are justified only if tumor recurrence is 
suspected.
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